The news of Citigroup maintaining a Neutral rating on CRISPR Therapeutics and raising the price target from $55 to $70 indicates that the analyst sees potential in the stock but remains cautious. This may not have a significant short-term impact on the stock price, as the rating remains unchanged. However, the increased price target may generate some positive sentiment among investors.